Upcoming Cell And Gene Therapy Milestones Are Expected To Transform Long Term Royalty Prospects

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

11 Dec 25

Updated

26 Jun 26

Views

Not Invested

Shared on 26 Jun 26

Fair value Decreased 39%

MXCT: Partnership Progress And Buybacks Will Support Future Upside

MaxCyte inks a new partner deal aimed at improving how gene changes are delivered into cells, and early results point to healthier, better-performing cells than older approaches. It also launches a share buyback plan and maintains its revenue outlook, even as analysts dial back their expectations for the company’s longer-term upside.

3 views

Fair Value vs Share Price

US$4.11

vs US$1.2868.8% undervalued

14.9%

Revenue growth

15.6%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on MaxCyte

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with concerning outlook.

Market capUS$138.2m

PB0.8x

Estimated Growth18.8%

Dividend YieldN/A

Full analysis

CEO & management

Maher Masoud

CEO

2.5yrs

CEO Tenure

A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.